Janux Therapeutics (JANX) Share-based Compensation (2020 - 2026)

Janux Therapeutics (JANX) has reported Share-based Compensation for 7 consecutive years, with $28.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Share-based Compensation rose 166.31% year-over-year to $28.5 million; the TTM figure through Mar 2026 stood at $28.5 million (down 25.19% YoY), while the FY2025 annual figure was $57.6 million, up 74.44% from the prior year.
• Share-based Compensation improved to $28.5 million in Q1 2026 per JANX's latest filing, from $9.5 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $75.9 million in Q2 2025 and bottomed at $4.0 million in Q1 2022.
• Historically, Share-based Compensation has averaged $15.1 million across 5 years, with a median of $5.6 million in 2024.
• Annual changes were most pronounced in 2022 — Share-based Compensation soared 1323.74% — and 2023, when it fell 1.04%.
• Janux Therapeutics' Share-based Compensation stood at $4.2 million in 2022, then rose by 6.61% to $4.5 million in 2023, then jumped by 39.44% to $6.3 million in 2024, then soared by 52.22% to $9.5 million in 2025, then soared by 199.53% to $28.5 million in 2026.
• Business Quant data shows JANX's Share-based Compensation at $28.5 million in Q1 2026, $9.5 million in Q4 2025, and $61.2 million in Q3 2025.